

## **1.3.1**

# **Summary of Product Characteristics (SmPC)**

## Module-1 Administrative Information and Product Information

### 1. Name of the medicinal Product

#### 1.1 Name of the medicinal Product

Combipack of Artesunate For Injection 120mg, Sodium Bicarbonate Injection BP 5% W/V & Sodium Chloride BP 0.9% W/V

#### 1.2 Strength

Each Combipack Contains:

(A) One Vial of Artesunate For Injection

Each Vial Contains:

Artesunate (sterile).....120 mg.

(B) One ampoule of 3 ml (Filled in 5 ml ampoule) Sodium Bicarbonate Injection BP 5.0 % w/v

Composition:

Sodium Bicarbonate BP.....5% w/v

Water for Injections BP.....Q.S.

(C) One ampoule of 7.5 ml (filled in 10 ml ampoule) Sodium Chloride Injection BP 0.9 % w/v

Composition:

Sodium Chloride BP.....0.9% w/v

Water for Injections BP.....Q.S.

### 2. Qualitative and Quantitative Composition

#### 2.1 Qualitative declaration

Artesunate

#### 2.2 Quantitative declaration

For Artesunate Injection 120 mg

Sr. No.	Ingredients	Specifications	Standard Quantity/ (mg/vial)	Reason for Inclusion
01	Artesunate	In-House	120.0	Antimalarial Agent

## Module-1 Administrative Information and Product Information

### For Sodium Bicarbonate Injection BP 0.5% w/v

Sr. No.	Ingredients	Specifications	Standard Quantity/ (%w/v)	Reason for Inclusion
01	Sodium Bicarbonate	BP	5.000	Alkalizing agent
02	Water for Injections	BP	Q.S.	Vehicle

### For Sodium Chloride Injection BP 0.9% w/v

Sr. No.	Ingredients	Specifications	Standard Quantity/ (%w/v)	Reason for Inclusion
01	Sodium Chloride	BP	0.900	Tonicity agent
02	Water for Injections	BP	Q.S.	Vehicle

### 3. Pharmaceutical Form

Dry Powder Injection

White to off white colour powder filled in 30 ml glass vial.

### 4. Clinical Particulars

#### 4.1 Therapeutic Indications

It is indicated for the treatment of severe malaria caused by Plasmodium falciparum, in adults and children.

#### 4.2 Posology and Method of Administration

**Adults and children:** Artesunate injection is administered at a dose of 2.4 mg of artesunate/kg body weight, by intravenous (I.V.) or intramuscular (I.M.) injection, at 0, 12 and 24 hours, then once daily until oral treatment can be substituted.

**Administration:** The powder for injection is difficult to dissolve and care should be taken to ensure that it is completely dissolved before parenteral administration

The formulation should be used immediately after reconstitution. If the solution is cloudy or precipitate is present, the parenteral solution should be discarded. Do not use water for injection

## Module-1 Administrative Information and Product Information

---

for reconstitution of the artesunate powder or for dilution of the resulting solution prior to injection.

The powder for injection should be reconstituted with 3 ml of sodium bicarbonate 5% w/v, shake vigorously till the solution become clear.

**For I.V. Use:** Add 15 ml of sodium chloride 0.9% w/v and mix again to prepare final concentration of 10 mg/ml for I.V. use. The required amount of drug for I.V. use should be administered slowly over a period of 2-3 minutes.

**For I.M. Use:** Add 6 ml of sodium chloride 0.9% w/v and mix again to prepare final concentration of 20 mg/ml for I.M. use.

### 4.3 Contraindications

It is contraindicated in patients with hypersensitivity to artesunate or other artemisinin derivatives.

### 4.4 Special Warnings and Special Precautions for Use

**Non-falciparum malaria:** Artesunate has not been evaluated in the treatment of severe malaria due to *Plasmodium vivax*, *Plasmodium malariae* or *Plasmodium ovale*.

In cerebral malaria and complicated malaria, general supporting therapy is usually required.

**Renal/hepatic impairment:** Dose adjustment is not necessary in patients with hepatic or renal impairment.

**Pregnancy:** There has been limited clinical experience with the use of artesunate in pregnancy. In animal studies, artesunate has been associated with foetal toxicity during the first trimester of pregnancy. To date, clinical data regarding safety in the first trimester have not indicated an increased risk of foetal harm. Treatment with artesunate should not be withheld during the first trimester if it is potentially life-saving for the mother.

**Lactation:** The active metabolite of artesunate is excreted at low levels in breast milk. The drug levels are not expected to cause any adverse effects in breast fed infants. The amount of drug present in breast milk does not protect the infant from malaria.

### 4.5 Interaction with other medicinal products and other forms of interaction

Few clinical drug-drug interaction studies have been performed; however no clinically significant interactions have been identified.

#### **4.6 Fertility, Pregnancy and Lactation**

**Pregnancy:** There has been limited clinical experience with the use of artesunate in pregnancy. In animal studies, artesunate has been associated with foetal toxicity during the first trimester of pregnancy. To date, clinical data regarding safety in the first trimester have not indicated an increased risk of foetal harm. Treatment with artesunate should not be withheld during the first trimester if it is potentially life-saving for the mother.

**Lactation:** The active metabolite of artesunate is excreted at low levels in breast milk. The drug levels are not expected to cause any adverse effects in breast fed infants. The amount of drug present in breast milk does not protect the infant from malaria.

#### **4.7 Effects on ability To Drive and use Machines**

No such information has been reported.

#### **4.8 Undesirable Effects:**

**Blood and lymphatic systems disorders:** Neutropenia and anaemia (both occasionally severe), thrombocytopenia, pure red cell aplasia, post-treatment anaemia, mild and transient decrease in reticulocyte count.

**Nervous system disorders:** Dizziness, light-headaches, headache, insomnia, tinnitus, peripheral neuropathy.

**Respiratory disorders:** Cough, nasal symptoms

**Gastrointestinal disorders:** Altered taste, nausea, vomiting, abdominal pain or cramps, diarrhoea, raised serum amylase, pancreatitis.

**Hepatobiliary disorders:** Transient rises in liver transaminases (AST, ALT), hepatitis.

**Skin and subcutaneous tissue disorders:** Rash, alopecia.

**Musculoskeletal and connective tissue disorders:** Arthralgia, muscle disorders

**General disorders and administration site conditions:** Fatigue, malaise, fever, pain at injection site.

**Immune system disorders:** Hypersensitivity

#### **4.9 Overdose**

## Module-1 Administrative Information and Product Information

---

Experience of acute overdose with artesunate is limited. The overdose of artesunate is associated with pancytopenia, melena, seizures, multi organ failure and death. Treatment of overdose should consist of general supportive measures.

### 5. Pharmacological Properties

#### 5.1 Pharmacodynamics Properties

Artesunate is a hemisuccinate derivative of dihydro-artemisinin, which is itself formed by the reduction of artemisinin. The mechanism of action of the artemisinins likely involves cleavage of the internal endoperoxide bridge through reaction with haeme within the infected erythrocyte, thereby generating free radicals which alkylate vital parasite proteins. However, artemisinins have also been reported to inhibit an essential parasite calcium adenosine triphosphatase. The artemisinins are distinguished from other antimalarials by their ability to kill all erythrocytic stages of the malaria parasite, including the relatively inactive ring stage and late schizonts, as well as the gametocytes responsible for malaria transmission. Artesunate and the artemisinins are the most rapid acting of the antimalarials, and they have also been shown to enhance splenic clearance of infected erythrocytes by reducing cytoadherence.

#### 5.2 Pharmacokinetic Properties

**Absorption:** After intravenous injection artesunate is very rapidly biotransformed to its active metabolite, dihydroartemisinin (DHA). Consequently, artesunate half-life ( $t_{1/2}$ ) is estimated to be less than 5 minutes. Artesunate is rapidly absorbed following intramuscular injection, and peak plasma levels are generally achieved within 30 minutes of administration.

**Distribution:** Dihydroartemisinin (DHA) has been shown to substantially accumulate in *P. falciparum* infected erythrocytes. Plasma protein binding of dihydroartemisinin is determined to be 93% in patients and 88% in healthy volunteers.

**Metabolism Elimination:** Artesunate is extensively and rapidly hydrolysed by plasma esterases, with possible minimal contribution by CYP2A6. The main metabolite, dihydroartemisinin, accounts for most of the in vivo antimalarial activity of IV administration.

DHA is further metabolized in the liver via glucuronidation and is excreted in the urine; a-dihydroartemisinin-P-glucuronide has been identified as the major urinary product in patients with *falciparum* malaria.

## **Module-1 Administrative Information and Product Information**

---

### **5.3 Preclinical Safety Data**

Not applicable.

## **6. Pharmaceutical Particulars**

### **6.1 List of Excipients**

Sodium Bicarbonate BP

Sodium Chloride BP

Water For Injections BP

### **6.2 Incompatibilities**

Not applicable.

### **6.3 Shelf Life**

36 months

### **6.4 Special Precautions for Storage**

Store below 30°C. Protect from light and moisture.

### **6.5 Nature and Contents of Container**

A white powder filled in 30 ml clear glass USP type-I vial having 20 mm grey butyl rubber stopper & 20 mm yellow F/O seal. Such one vial is packed in a Tray Pack with one ampoule of 3 ml (filled in 5ml ampoule) Sodium Bicarbonate Injection BP 5% w/v & two ampoules of 7.5 ml (filled in 10 ml ampoule) Sodium Chloride Injection BP 0.9% w/v, such one Tray is packed in a Printed Carton with Packaging Insert.

### **6.6 Special precaution for disposal and other handling**

Any unused product or waste material should be disposed of in accordance with local requirements.

## **7. Registrant (Marketing Authorization Holder And Manufacturing Site Addresses)**

### **7.1 Name and Address of Marketing Authorization Holder**

**ZOLON HEALTHCARE LTD.**

37 OSOLO WAY, AJAO ESTATE ,  
ISOLO, LAGOS,  
NIGERIA.

E-mail: [info@zolonhealthcare.com](mailto:info@zolonhealthcare.com)

**7.2 Name and Address of manufacturing site(s)**

LINCOLN PARENTERAL LTD.

11, Trimul Estate, Khatraj, Tal. Kalol,

District: Gandhinagar Gujarat, India.

Telephone no.: +91-07949-135000

Fax: +91-07941-078062

Email: [info@lincolnpharma.com](mailto:info@lincolnpharma.com)

Website: [www.lincolnpharma.com](http://www.lincolnpharma.com)

**7.3 Marketing Authorization Number**

To be included after obtaining first registration.

**7.4 Date of First <Registration> / Renewal of The <Registration>**

It will be applicable after registration of this product.

**8. Date of Revision of the Text**

----

**9. Dosimetry (If Applicable)**

Not Applicable

**10. Instructions for preparation of radiopharmaceuticals (if Applicable)**

Not Applicable